Compare Byrna Technologies Inc (BYRN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Zoetis Inc — how do they compare? Byrna Technologies Inc trades at $4.26 (market cap $106.74M), while Zoetis Inc trades at $73.85 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 291.7× Byrna Technologies Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | ZTS | |
|---|---|---|
Market Cap | $106.74M | $31.14B |
Sector | Technology | Health |
52-Week High | $27.63 | $156.76 |
52-Week Low | $3.18 | $71.91 |
Enterprise Value | $98.35M | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.25, down 12.37% on the day, reflecting investor reaction to recent earnings misses and revenue declines. The stock shows a bullish technical signal with strong moving average support, but fundamentals are mixed with a negative net income margin of -3.39% and ROE of -6.3% for 2026. Recent management changes and strategic acquisitions aim to revitalize growth amid sales challenges highlighted in Q2 2026 results.
The outlook remains cautious due to execution risks in marketing turnaround and competitive pressures. Analyst consensus is 71% buy, but investors face volatility from ongoing investigations and weak quarterly performance. Upside depends on successful brand repositioning and retail expansion under new leadership.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
